The estimated Net Worth of Jason A Keyes is at least $388 Thousand dollars as of 16 July 2024. Mr. Keyes owns over 10,000 units of Equillium Inc stock worth over $58,205 and over the last 8 years he sold EQ stock worth over $330,040. In addition, he makes $0 as Chief Financial Officer at Equillium Inc.
Sign up
Mr. Keyes EQ stock SEC Form 4 insiders trading
Jason has made over 13 trades of the Equillium Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of EQ stock worth $8,700 on 16 July 2024.
The largest trade he's ever made was selling 10,000 units of Equillium Inc stock on 16 July 2024 worth over $8,700. On average, Jason trades about 2,455 units every 55 days since 2016. As of 16 July 2024 he still owns at least 67,720 units of Equillium Inc stock.
You can see the complete history of Mr. Keyes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jason Keyes biography
Jason A. Keyes serves as Chief Financial Officer of the Company. From January 2013 to February 2018, Mr. Keyes held positions of increasing responsibility at Orexigen Therapeutics, Inc., a publicly-held pharmaceutical company which filed a voluntary petition for Chapter 11 bankruptcy in March 2018, most recently as Executive Vice President and Chief Financial Officer. Mr. Keyes held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from August 2007 until January 2013, most recently as Senior Director of Finance. Prior to joining Amylin, Mr. Keyes held positions of increasing responsibility in finance and corporate strategy at Amgen Inc., a publicly-held biopharmaceutical company, and Baxter Healthcare Corporation, a publicly-held healthcare company. Mr. Keyes has served as a director of Sesen Bio, Inc., a publicly-held biopharmaceutical company, since February 2020. Mr. Keyes received his B.S. and M.S. degrees in Civil Engineering from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.
How old is Jason Keyes?
Jason Keyes is 49, he's been the Chief Financial Officer of Equillium Inc since 2018. There are 12 older and 5 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.
What's Jason Keyes's mailing address?
Jason's mailing address filed with the SEC is 2223 AVENIDA DE LA PLAYA, SUITE 105, , LA JOLLA, CA, 92037.
Insiders trading at Equillium Inc
Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski, and Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.
What does Equillium Inc do?
equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.
What does Equillium Inc's logo look like?
Complete history of Mr. Keyes stock trades at Sesen Bio and Equillium Inc
Equillium Inc executives and stock owners
Equillium Inc executives and other stock owners filed with the SEC include:
-
Krishna Polu,
Executive Vice President - Research and Development, Chief Medical Officer -
Bruce Steel,
President, Chief Executive Officer, Director -
Daniel Bradbury,
Executive Chairman of the Board -
Dr. Krishna R. Polu,
Consultant -
Dr. Stephen Connelly Ph.D.,
Chief Scientific Officer & Director -
Bruce D. Steel C.F.A.,
Co-Founder, Pres, CEO & Director -
Stephen Connelly,
Chief Scientific Officer, Director -
Daniel Mark Bradbury,
Exec. Chairman -
Mark Pruzanski,
Independent Director -
Charles McDermott,
Independent Director -
Bala Manian,
Independent Director -
Martha Demski,
Independent Director -
Matthew Ritter,
Vice President - Corporate Development -
Maple Fung,
Vice President - Clinical Development -
Christine Zedelmayer,
Chief Operating Officer, Senior Vice President -
Jason Keyes,
Chief Financial Officer -
Jason A. Keyes,
Chief Financial Officer -
Dr. Dolca Thomas M.D.,
Exec. VP of R&D and Chief Medical Officer -
Joel M. Rothman,
Chief Devel. Officer -
Michael Moore,
VP of Investor Relations & Corp. Communications -
Christine Zedelmayer M.B.A., P.M.P.,
Sr. VP & COO -
Yu (Katherine) Xu,
-
Sa Biocon,
10% owner -
Dolca Thomas,
Chief Medical Officer -
Joel Rothman,
Chief Development Officer -
Barbara Troupin,